The study found that the combination of paclitaxel and bevacizumab significantly improved progression-free survival compared to paclitaxel alone. Patients in the experimental arm had a longer median PFS, demonstrating the potential benefit of adding bevacizumab to standard chemotherapy. However, overall survival did not show a statistically significant improvement. Additionally, the combination treatment was associated with a higher incidence of adverse effects such as hypertension and proteinuria.
